SPOT-MAS Multi-Cancer Early Detection Blood Test
Key Takeaways
- SPOT-MAS is a simple blood test that screens for 10 common and aggressive cancers
- Uses advanced next-generation sequencing and AI to analyse circulating tumour DNA (ctDNA)
- High specificity (99.8%) with clinically validated data from over 9,000 participants in Asia
- Requires only one blood draw and results are reviewed with your doctor
- Complements regular cancer screening by covering cancers without standard screening options
What Is SPOT-MAS?
SPOT-MAS is a non-invasive multi cancer early detection (MCED) test that checks your blood for circulating tumour DNA (ctDNA). Tumour cells release these DNA fragments into the bloodstream, and this technology allows us to detect them early.
Unlike traditional cancer screening options in Singapore that focus on one organ at a time, SPOT-MAS examines multiple ctDNA features through advanced sequencing and AI to identify potential cancer signals and suggest the possible tumour origin.
It screens for early signals of 10 common and aggressive cancers:
- Breast
- Lung
- Colorectal
- Stomach
- Liver biliary tract
- Ovary
- Pancreas
- Oesophagus
- Uterus
- Head and Neck
Cancer Is Most Treatable When Caught Early
Many people still believe that cancer inevitably leads to death. In many cases, poorer outcomes often linked to late detection rather than a lack of advance treatment options.
Early cancer detection can make a significant difference:
- Survival can be up to 4 times higher
- Early breast and colorectal cancers have over 90 percent survival
- Treatment is often less costly
Why SPOT-MAS?
SPOT-MAS is designed to complement your regular health screening routine, adding a deeper layer of early detection.
- Screens for 10 cancers
7 out of the 10 cancers currently have no standard-of-care screening in Singapore. SPOT-MAS fills this gap by identifying cancer signals that might otherwise go unnoticed. - High accuracy
99.8% specificity, a 99.9% negative predictive value, and an 84% accuracy in predicting the likely tumour origin. - Clinically validated
SPOT-MAS has been studied in over 9,000 participants in Asia. - Simple and convenient
Only one tube of blood is needed for comprehensive screening.
Your SPOT-MAS test Journey
The SPOT-MAS test follows a simple three step process:
- Doctor Consultation
SPOT-MAS is available after consultation with a doctor at our GP clinic. You will be required to complete a consent form prior to taking the test. - A Single Blood Draw
A simple blood draw is performed in the clinic. Only 10ml of blood is required. - Advanced DNA analysis
Your blood sample is analysed using next-generation sequencing. Multiple circulating tumour DNA (ctDNA) features are assessed to identify any cancer signals. - Results and Follow-Up
Laboratory analysis takes approximately 12 working days, followed by 1 to 3 working days for the hardcopy report to reach the clinic. Once your doctor receives the report, you will be contacted to return for a review and discussion of the next steps.
How Is SPOT-MAS Different from Tumour Marker Blood Tests?
Tumour marker blood tests and SPOT-MAS are both blood-based tests, but they detect different biological signals and serve different roles in cancer care.
Traditional tumour marker blood tests, such as PSA or CA-125, measure certain proteins that may be elevated in some cancers.
SPOT-MAS takes a different approach. It is a blood-based multi-cancer early detection test that analyses circulating tumour DNA (ctDNA) released by cancer cells. Instead of focusing on one organ, it screens for multiple cancer types from a single blood draw.
SPOT-MAS vs Tumour Marker Blood Tests
Because these tests detect cancer in different ways and are used at different stages of care, understanding their differences helps you make informed decisions about your health screening plan.
| Feature | Cancer Markers | SPOT-MAS |
|---|---|---|
| Analyte | Proteins/Hormones (typically) | ctDNA (genetic material) |
| Technology | Immunoassays | Next-Generation Sequencing & AI |
| Primary Use | Monitoring/Prognosis | Early Detection (Screening) |
| Specificity | Lower (Higher false positives, elevated levels when no cancer is present, as can rise due to non-cancerous, benign conditions (e.g., prostatitis, endometriosis).) | High (99.8%) |
| Coverage | Usually specific to one organ | At least 10 organs screened |
Early Cancer Detection with One Blood Test
SPOT-MAS Multi-Cancer Early Detection Blood Test
Price: S$870.91 Nett
Screens for 10 cancers with high specificity and reliable ctDNA analysis, including:
- Breast
- Lung
- Colorectal
- Stomach
- Liver biliary tract
- Ovary
- Pancreas
- Oesophagus
- Uterus
- Head and Neck
Frequently Asked Questions about SPOT-MAS
SPOT-MAS is recommended for:
- Adults aged 40 and above
- Adults under 40 with higher risks, such as:
- Heavy smoking
- Heavy alcohol intake
- Family history of cancer
- Liver diseases such as Hepatitis B or C
- Known hereditary cancer gene mutations (e.g. BRCA1, BRCA2, TP53)
Your doctor can advise whether this test suits your health profile.
This test is not recommended for:
- Individuals diagnosed with cancer within the last 5 years
- Anyone with strong signs of cancer on imaging or clinical findings
- Pregnant individuals
- Individuals who recently had a blood transfusion or bone marrow transplant (within the last 3 months)
No. SPOT-MAS is a screening tool. A positive result means a cancer signal was detected, but it does not confirm that cancer is present. Further imaging or diagnostic tests are required to confirm the finding.
A negative result means no cancer signal was detected at the time of testing. However, this does not guarantee zero cancer risk in the future. You should continue annual health checks and regular age-appropriate cancer screening.
A positive result indicates that ctDNA associated with tumour cells was detected. The report may include one to two predictions of where the tumour might be located. Further confirmatory tests, such as imaging or biopsy, will be advised by your doctor.
An intermediate result is uncommon. It means the ctDNA level falls in the borderline range. A free repeat test is recommended within six months, and you should continue with routine health checks.
No. SPOT-MAS complements, not replaces, standard screenings such as mammograms, colonoscopies, or Pap smears. It helps detect cancers that may not have an existing screening method.
An annual test is recommended. Cancer signals can change over time, so regular screening helps ensure consistent monitoring.
